Pharmacokinetic Parameters of Oral Pegylated IFN-λ1

We studied the pharmacokinetics of a pegylated IFN-λ1 (PEG IFN-λ1) after its oral administration to rats in different therapeutic doses. The hypothesis on linear pharmacokinetics of PEG IFN-λ1 within the dose range of 2.6-7.8 μg/kg was confirmed, high for protein molecules bioavailability from 17.5...

Descripción completa

Detalles Bibliográficos
Autores principales: Sherstoboev, E. Yu., Oleinik, L. A., Zhdanov, V. V., Kikhtenko, N. A., Madonov, P. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218048/
https://www.ncbi.nlm.nih.gov/pubmed/35737159
http://dx.doi.org/10.1007/s10517-022-05521-3
_version_ 1784731790868480000
author Sherstoboev, E. Yu.
Oleinik, L. A.
Zhdanov, V. V.
Kikhtenko, N. A.
Madonov, P. G.
author_facet Sherstoboev, E. Yu.
Oleinik, L. A.
Zhdanov, V. V.
Kikhtenko, N. A.
Madonov, P. G.
author_sort Sherstoboev, E. Yu.
collection PubMed
description We studied the pharmacokinetics of a pegylated IFN-λ1 (PEG IFN-λ1) after its oral administration to rats in different therapeutic doses. The hypothesis on linear pharmacokinetics of PEG IFN-λ1 within the dose range of 2.6-7.8 μg/kg was confirmed, high for protein molecules bioavailability from 17.5 to 21%, the absence of intravascular deposition, and effective elimination with feces and urine (85 and 15% of the administered dose, respectively) were demonstrated. At the same time, the mean retention time for PEG IFN-λ1 in the circulation is 6.46-6.65 h and half-life is 3 h. These findings give ground for continuing experimental studies of PEG IFN-λ1 pharmacokinetics, in particular, tissue distribution of the drug.
format Online
Article
Text
id pubmed-9218048
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-92180482022-06-23 Pharmacokinetic Parameters of Oral Pegylated IFN-λ1 Sherstoboev, E. Yu. Oleinik, L. A. Zhdanov, V. V. Kikhtenko, N. A. Madonov, P. G. Bull Exp Biol Med Article We studied the pharmacokinetics of a pegylated IFN-λ1 (PEG IFN-λ1) after its oral administration to rats in different therapeutic doses. The hypothesis on linear pharmacokinetics of PEG IFN-λ1 within the dose range of 2.6-7.8 μg/kg was confirmed, high for protein molecules bioavailability from 17.5 to 21%, the absence of intravascular deposition, and effective elimination with feces and urine (85 and 15% of the administered dose, respectively) were demonstrated. At the same time, the mean retention time for PEG IFN-λ1 in the circulation is 6.46-6.65 h and half-life is 3 h. These findings give ground for continuing experimental studies of PEG IFN-λ1 pharmacokinetics, in particular, tissue distribution of the drug. Springer US 2022-06-23 2022 /pmc/articles/PMC9218048/ /pubmed/35737159 http://dx.doi.org/10.1007/s10517-022-05521-3 Text en © Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Sherstoboev, E. Yu.
Oleinik, L. A.
Zhdanov, V. V.
Kikhtenko, N. A.
Madonov, P. G.
Pharmacokinetic Parameters of Oral Pegylated IFN-λ1
title Pharmacokinetic Parameters of Oral Pegylated IFN-λ1
title_full Pharmacokinetic Parameters of Oral Pegylated IFN-λ1
title_fullStr Pharmacokinetic Parameters of Oral Pegylated IFN-λ1
title_full_unstemmed Pharmacokinetic Parameters of Oral Pegylated IFN-λ1
title_short Pharmacokinetic Parameters of Oral Pegylated IFN-λ1
title_sort pharmacokinetic parameters of oral pegylated ifn-λ1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218048/
https://www.ncbi.nlm.nih.gov/pubmed/35737159
http://dx.doi.org/10.1007/s10517-022-05521-3
work_keys_str_mv AT sherstoboeveyu pharmacokineticparametersoforalpegylatedifnl1
AT oleinikla pharmacokineticparametersoforalpegylatedifnl1
AT zhdanovvv pharmacokineticparametersoforalpegylatedifnl1
AT kikhtenkona pharmacokineticparametersoforalpegylatedifnl1
AT madonovpg pharmacokineticparametersoforalpegylatedifnl1

Ejemplares similares